U.S. FDA warns against malaria drugs Trump championed for COVID-19

(Reuters) - The U.S. Food and Drug Administration on Friday cautioned against the use of malaria drug hydroxychloroquine, touted by President Donald Trump, in COVID-19 patients outside of hospitals and clinical trials, citing risks of serious heart rhythm problems.The decades-old drug has been called a "game changer" by Trump in the fight against the novel coronavirus and anecdotal reports that it may provide some benefit have spurred sales of the drug.There is no evidence yet of the drugs'..